STAT3 Inhibition in Cancer: A Review of Emerging Therapeutics
Journal of Cancer Biomoleculars and Therapeutics · 2025
DOI: 10.62382/jcbt.v2i2.63 ↗Abstract
Abnormal signal transducer and transcriptional activator (STAT3) activation occurs in many human tumors. Therefore, targeting STAT3 signaling has emerged as a promising therapeutic approach for treating many cancers. In addition, studies using genetic and pharmacological agents to alter the activity of STAT3 provide significant evidence for the role of STAT3 dysfunction. in malignant transformation and cancer, confirming STAT3 as a novel cancer target. In this review, we provide an outline of the importance of targeting the STAT3 signaling pathway, the mechanism of action of inhibitors, and the current development of STAT3-targeted drug therapy. We also summarize the efforts to provide new insights into the translation of STAT3 in cancer and may contribute to better treatments for these malignancies. The main purpose of this review is to provide a general framework for the development of STAT3 inhibitors and a discussion of the inhibition mechanisms developed.
EUVIMED